TP53 and neoplasm: A comprehensive risk assessment model incorporating multiple parameters—including depth of submucosal infiltration (sm1 versus sm2/3), tumor budding characteristics, and molecular markers (e.g., p53 mutation status)—could optimize patient selection for additional surgical intervention (23–25).